 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Duggan
Veterinary Supplies
Holycross
Thurles
Co Tipperary
Rep of Ireland
W:+353 (0)504 43169
FAX:+353 (0) 504 43147
E-mail:
info@dugganvet.ie
STARTVAC
EUROPEAN CENTRAL PRODUCT REGISTRATION
First vaccine against mastitis registered through the EMEA.The EMEA registration system is the most complete and thorough in the world. Its safety andefficacy tests are priorities for the confirmation the product, unlike other systems, such asthe American FDA, which only gives importance to placebo tests for controlling product
safety, but not its efficacy.
The programme’s conclusions are:
��
The EMEA is the most demanding registration system in the world.
��
First vaccine against mastitis, which has passed the requirements of the European
Agency.
��
Registered in 30 EU countries at the same time.
4.3. MICROORGANIMS INVOLVED (
E. COLI, S. AUREUS AND CNS) AND THE EFFECT OF THE
VACCINE ON THEM.STARTVAC
® acts differently depending on the microorganism.
E. coli
and coliforms: STARTVAC® acts by inhibiting the development of the cell wall, thereby
preventing bacterial growth. STARTVAC® acts against the CORE antigen at a specific time inthe growth of the wall, thus enhancing the recognition of the natural defences for the
destruction of the bacteria.
S. aureus
and CNS: STARTVAC® hinders the formation of SLIME. Slime or Biofilm is a layer of
exopolysaccharides that surrounds the bacteria, enhancing their growth and resistance toantibiotics. STARTVAC® prevents the development of SLIME and also favours contact withneutrophils, enabling the destruction of bacteria. Importance of immunization protocol and
benefits of vaccination.